Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BLRX |
---|---|---|
09:32 ET | 937 | 0.6847 |
09:34 ET | 440 | 0.6626 |
09:38 ET | 3840 | 0.6552 |
09:45 ET | 2000 | 0.6601 |
09:50 ET | 700 | 0.6602 |
09:54 ET | 300 | 0.6603 |
10:14 ET | 750 | 0.6602 |
10:17 ET | 407 | 0.6635 |
10:21 ET | 1200 | 0.6603 |
10:24 ET | 2315 | 0.6724 |
10:35 ET | 1993 | 0.6605 |
10:37 ET | 1200 | 0.6724 |
10:51 ET | 1000 | 0.6683 |
10:53 ET | 2956 | 0.689 |
11:00 ET | 400 | 0.6771 |
11:08 ET | 8925 | 0.6696 |
11:11 ET | 10100 | 0.6697 |
11:18 ET | 1500 | 0.6887 |
11:22 ET | 100 | 0.6704 |
11:27 ET | 500 | 0.679099 |
11:29 ET | 900 | 0.671 |
11:36 ET | 1000 | 0.672 |
11:44 ET | 5600 | 0.6751 |
11:45 ET | 500 | 0.6817 |
11:47 ET | 500 | 0.6752 |
11:51 ET | 250 | 0.675201 |
12:00 ET | 3586 | 0.6751 |
12:03 ET | 896 | 0.672 |
12:09 ET | 114 | 0.6721 |
12:20 ET | 1000 | 0.6745 |
12:25 ET | 858 | 0.673 |
12:27 ET | 700 | 0.6719 |
12:30 ET | 4380 | 0.6621 |
12:32 ET | 3700 | 0.6746 |
12:39 ET | 2800 | 0.662 |
12:41 ET | 339 | 0.662 |
12:52 ET | 750 | 0.6621 |
01:35 ET | 1465 | 0.6742 |
01:53 ET | 1000 | 0.669 |
01:55 ET | 300 | 0.669 |
02:29 ET | 1200 | 0.665 |
02:38 ET | 14184 | 0.6552 |
02:40 ET | 8644 | 0.65 |
02:42 ET | 1500 | 0.6502 |
03:05 ET | 11683 | 0.6513 |
03:07 ET | 300 | 0.659599 |
03:09 ET | 200 | 0.6514 |
03:16 ET | 750 | 0.659599 |
03:34 ET | 250 | 0.6596 |
03:36 ET | 500 | 0.65435 |
03:54 ET | 200 | 0.652 |
03:56 ET | 2000 | 0.6593 |
03:57 ET | 3615 | 0.6568 |
03:59 ET | 1000 | 0.652 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
BioLine RX Ltd | 52.7M | -0.7x | --- |
Palatin Technologies Inc | 37.0M | -0.9x | --- |
Kezar Life Sciences Inc | 56.3M | -0.6x | --- |
Kronos Bio Inc | 61.3M | -0.5x | --- |
Correlate Energy Corp | 50.6M | -3.5x | --- |
Dyadic International Inc | 42.4M | -6.1x | --- |
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.7M |
---|---|
Revenue (TTM) | $4.8M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.95 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 11.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,035.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.